MR1 and neoplasm: Additionally, research has shown that MR1-restricted TRAV1-2+ and TRAV26-1+ TCRs identified from the tumor-infiltrating T cells of breast cancer patients specifically respond to some breast cancer cell lines but not to other cancer types (68).